| Program | Target / Focus | Research | Preclinical | Clinical exploration | Global clinical development |
| MT027 | B7-H3 Recurrent glioblastoma | ||||
| MT027 | B7-H3 Brain metastases | ||||
| MT029 | EGFR Solid tumor | ||||
| MT026/MT028 | IL-13Rα2 / HER2 Solid tumors |
| Supporting development | MT027-CDx | B7-H3 IHC companion diagnostic: supporting patient selection and subsequent clinical development |
| *ODD: FDA Orphan Drug Designation (MT027 glioblastoma GBM) | # FTD: FDA Fast Track Designation (MT027 glioblastoma GBM) |